media – Page 521 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

UCSD launching pilot trial of glucose-sensing ‘tattoo’

Researchers from the University of California San Diego have developed a low-cost, single-use tattoo-like wearable that measures the user’s glucose levels. According to a release from the institution, this noninvasive technology will be at the center of a newly announced pilot clinical trial designed to test the accuracy and acceptability of the tattoos.
- Source: MobiHealthNews
- 599
- April 25, 2018
blood glucose Researches
Inventiva Raises €35.5 Million Through A Capital Increase With European And US Investors

Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announces the successful completion of the issuance of 5,572,500 new ordinary shares without preferential subscription rights (the "New Shares") for a total gross proceeds of approximately €35.5 million by means of a private placement reserved to a specified category of investors as described below (the "Reserved Offering"). The Reserved Offering was conducted by Jefferies International Limited, acting as Global Coordinator and Joint Bookrunner, and Société Générale Corporate & Investment Banking and Gilbert Dupont acting as Joint Bookrunners (together with the Global Coordinator and Joint Bookrunner, the "Managers"). Namsen Capital acted as Inventiva's Capital Markets Advisor.
- Source: drugdu
- 605
- April 24, 2018
Market Views MPS NASH Series SSc
FDA ‘conflicted’ on Lilly and Incyte’s refiled baricitinib

Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib could be scuppered again by lingering FDA concerns about safety. A briefing document published ahead of the April 23 advisory committee meeting on baricitinib suggests that Lilly and Incyte’s lightning-fast amendment and refile of the dossier hasn’t added enough data to persuade the FDA to change its stance on the risk of blood clots with the JAK inhibitor.
- Source: Fiercebiotech; new approvals
- 616
- April 24, 2018
baricitinib Eli Lilly FDA rheumatoid arthritis
Next year’s flu shot will shield only 20% against dominant strain

Recent doubts about traditional egg-based flu shots could mean more business for vaccines manufactured in cells. Protection against the dominant H3N2 flu strain offered by the coming season’s flu vaccine will still be far from optimal—putting it mildly. And that's thanks to the widely used manufacturing process based on eggs, a new study predicts.
- Source: fiercepharma
- 665
- April 24, 2018
H3N2 flu strain Researches vaccine
NEJM editorial slams design of GSK’s pivotal trial of 3-in-1 COPD drug Trelegy

GSK is shifting resources towards key therapeutic classes, including respiratory disease.
- Source: fiercepharma.
- 596
- April 24, 2018
Company Insight GSK respiratory disease Trelegy Ellipta
Healthcare startups take on the challenge of improving medical equipment delivery, tracking

When Parachute Health founder and CEO David Gelbard’s father was discharged from the hospital following spine surgery, the hospital ordered a walker to assist him as he recovered. But for weeks, it didn’t arrive and Gelbard’s father subsequently fell, adding years to his rehabilitation.
- Source: MedCityNews
- 499
- April 24, 2018
Company Insights medical device products
How health apps factor into a $950B ecosystem

Highlighting the ubiquity and importance of smartphones across multiple industries, a new report by ACT | The App Association indicated that two out of three businesses utilize enterprise apps. And many of those opportunities are rising up throughout the healthcare industry.
- Source: Fierce Healthcare
- 632
- April 24, 2018
healthcare Market Views mHealth
mHealth App Aims to Help Caregivers Identify Perinatal Depression

The mHealth app, designed by researchers at the Worcester Polytechnic Institute, helps obstetric care providers identify perinatal depression in soon-to-be and new mothers and gives them care management tips.
- Source: mHealth Intelligence
- 644
- April 24, 2018
mHealth New Approvals pregnancy
Novartis pads case for new MS blockbuster with disease-progression analysis

Novartis is hoping multiple sclerosis candidate siponimod’s performance in secondary progressive patients can help it secure a blockbuster approval. And now it has more data to put toward that case.
- Source: fiercepharma
- 540
- April 23, 2018
blockbuster Company Insight multiple sclerosis
Allergan swoops in as Takeda’s third Shire bid falls short at $61B

Three of Takeda’s anticipated Shire buyout bids have already been rejected—and now, the Japanese drugmaker might just lose out to a competing bidder. Allergan, for instance, is already in talks for a buy.
- Source: fiercepharma
- 507
- April 23, 2018
drugmaker Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.